The present application relates to a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions comprising same. The use of such compounds, pharmaceutically acceptable salts thereof or pharmaceutical compositions for inhibiting the activity of an IL-I receptor in a cell, or for treating IL-1 related diseases, disorders or conditions such as inflammatory diseases in a subject, is also described.
The present application relates to a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions comprising same. The use of such compounds, pharmaceutically acceptable salts thereof or pharmaceutical compositions for inhibiting the activity of an IL-I receptor in a cell, or for treating IL-1 related diseases, disorders or conditions such as inflammatory diseases in a subject, is also described.
The present application relates to a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions comprising same. The use of such compounds, pharmaceutically acceptable salts thereof or pharmaceutical compositions for inhibiting the activity of an IL-1 receptor in a cell, or for treating IL-1 related diseases, disorders or conditions such as inflammatory diseases in a subject, is also described.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
3.
INTERLEUKIN-1 RECEPTOR MODULATORS AND USES THEREOF
The present application relates to a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions comprising same. The use of such compounds, pharmaceutically acceptable salts thereof or pharmaceutical compositions for inhibiting the activity of an IL-1 receptor in a cell, or for treating IL-1 related diseases, disorders or conditions such as inflammatory diseases in a subject, is also described.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
There is provided a pH responsive optical nanoprobe comprising metallic SWCNTs or graphene coated with a transition metal M. The coated metallic SWCNTs or graphene have an absorption spectrum comprising an optical resonance, and have a Raman scattering spectrum responsive to optical excitation at said optical resonance comprising at least one pH-dependent peak having at least one of a Raman shift value and an intensity that is function of a solution pH, when the nanoprobe is in contact with a solution at said solution pH. There is also provided a method to measure the pH of a solution, by contacting the solution with the nanoprobe; illuminating the nanoprobe with an excitation light beam having a wavelength at said optical resonance, thereby generating a Raman signal from the nanoprobe according to said Raman scattering spectrum; measuring a spectral distribution of the Raman signal; and determining the pH of the solution from the spectral distribution.
There is provided a pH responsive optical nanoprobe comprising metallic SWCNTs coated with a transition metal M. The coated metallic SWCNTs have an absorption spectrum comprising a Raman resonance, and have a Raman scattering spectrum responsive to optical excitation at said Raman resonance comprising at least one pH-dependent peak having at least one of a Raman shift value and an intensity that is function of a solution pH, when the nanoprobe is in contact with a solution at said solution pH. There is also provided a method to measure the pH of a solution, by contacting the solution with the nanoprobe; illuminating the nanoprobe with an excitation light beam having a wavelength at said Raman resonance, thereby generating a Raman signal from the nanoprobe according to said Raman scattering spectrum; measuring a spectral distribution of the Raman signal; and determining the pH of the solution from the spectral distribution.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventor
Martel, Richard
Gaufrès, Étienne
Allard, Charlotte
Abstract
A fluorescent probe having a capsule of nanometric size and an aggregate of fluorogenic molecules coupled to the capsule is provided. The aggregate emits a fluorescent signal at one or more wavelengths within the fluorescence spectral range when the probe is illuminated by an excitation light beam at one or more wavelengths within the excitation spectral range. Preferably, the fluorescent spectral range is in the near-infrared region of the spectrum. In some embodiments, the capsule is a boron nitride (BN) nanotube and the aggregate comprise 3,6-Bis[2,2′]bithiophenyl-5-yl-2,5-di-n-octylpyrrolo[3,4-c]pyrrole-1,4-dione as fluorogenic molecules. In some embodiments, the 3,6-Bis[2,2′]bithiophenyl-5-yl-2,5-di-n-octylpyrrolo[3,4-c]pyrrole-1,4-dione fluorogenic molecules are in a J-aggregation state.
A fluorescent probe having a capsule of nanometric size and an aggregate of fluorogenic molecules coupled to the capsule is provided. The aggregate emits a fluorescent signal at one or more wavelengths within the fluorescence spectral range when the probe is illuminated by an excitation light beam at one or more wavelengths within the excitation spectral range. Preferably, the fluorescent spectral range is in the near-infrared region of the spectrum. In some embodiments, the capsule is a boron nitride (BN) nanotube and the aggregatecom prise 3,6-B is[2,2]bithiopheny1-5-yl-2,5-di-n-octylpyrrolo[3,4-c]pyrrole-1 ,4-dione as fluorogenic molecules. In some embodiments, the 3,6-Bis[2,2]bithiopheny1-5-yl-2,5-di-n-octylpyrrolo[3,4-c]pyrrole-1,4-dione fluorogenic molecules are in a J-aggregation state.
The present disclosure concerns detection systems which are kinetically controlled. In the systems of the present disclosure, the systems are kinetically controlled by a first association constant (k1) between the targeting oligonucleotide and the target, a second association constant (k2) between the targeting oligonucleotide and the signaling oligonucleotide and a third association constant (k3) between the signaling oligonucleotide and an anchoring nucleotide. The system is configured such that k1>k2>k3.
A mixture of polymers with lubricating properties is provided. The polymer can be used to produce a lubricating fluid. They can also be born on a surface or embedded in a porous material. This mixture of polymers comprises (a) a pharmaceutically acceptable bottle-brush polymer comprising a backbone with polymeric pendant chains, and (b) a pharmaceutically acceptable linear polymer. In the lubricating fluid, the bottle-brush polymer and the linear polymer are dissolved together in a pharmaceutically acceptable solvent.
C08L 51/00 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers
A61L 31/14 - Materials characterised by their function or physical properties
C10M 107/44 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
C10M 107/48 - Lubricating compositions characterised by the base-material being a macromolecular compound containing phosphorus
C10M 173/02 - Lubricating compositions containing more than 10% water not containing mineral or fatty oils
C10N 40/00 - Specified use or application for which the lubricating composition is intended
C10N 50/02 - Form in which the lubricant is applied to the material being lubricated dissolved or suspended in a carrier which subsequently evaporates to leave a lubricant coating
10.
Chalcogen-grafted carbon materials and processes for their preparation
Chalcogen-grafted carbon material as well as their functionalized forms are described along with processes for their preparation. More specifically, the chalcogen is covalently linked to the carbon scaffold of a polyaromatic carbon via C═X and/or C—X—C bonds. Processes for their preparation include a single thermal treatment without the use of strong acids or anhydrous solvents.
Chalcogen-grafted carbon material as well as their functionalized forms are described along with processes for their preparation. More specifically, the chalcogen is covalently linked to the carbon scaffold of a polyaromatic carbon via C=X and/or C-X-C bonds. Processes for their preparation include a single thermal treatment without the use of strong acids or anhydrous solvents.
Chalcogen-grafted carbon material as well as their functionalized forms are described along with processes for their preparation. More specifically, the chalcogen is covalently linked to the carbon scaffold of a polyaromatic carbon via C=X and/or C-X-C bonds. Processes for their preparation include a single thermal treatment without the use of strong acids or anhydrous solvents.
The present disclosure concerns detection systems which are kinetically controlled. In the systems of the present disclosure, the systems are kinetically controlled by a first association constant (k1) between the targeting oligonucleotide and the target, a second association constant (k2) between the targeting oligonucleotide and the signaling oligonucleotide and a third association constant (k3) between the signaling oligonucleotide and an anchoring nucleotide. The system is configured such that k1 > k2 > k3.
It is provided a substrate such as a microscopic slide coated with a layer of metal, such as chrome, titanium or aluminum, particularly a layer of less than 5 nm, or between 3 nm and 1 nm for adhering a sample, such as a tissue sample.
A mixture of polymers with lubricating properties is provided. The polymer can be used to produce a lubricating fluid. They can also be born on a surface or embedded in a porous material. This mixture of polymers comprises (a) a pharmaceutically acceptable bottle-brush polymer comprising a backbone with polymeric pendant chains, and (b) a pharmaceutically acceptable linear polymer. In the lubricating fluid, the bottle-brush polymer and the linear polymer are dissolved together in a pharmaceutically acceptable solvent.
C08L 51/00 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers
A61L 31/14 - Materials characterised by their function or physical properties
C10M 107/44 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
C10M 107/48 - Lubricating compositions characterised by the base-material being a macromolecular compound containing phosphorus
C10M 173/02 - Lubricating compositions containing more than 10% water not containing mineral or fatty oils
C10N 40/00 - Specified use or application for which the lubricating composition is intended
C10N 50/02 - Form in which the lubricant is applied to the material being lubricated dissolved or suspended in a carrier which subsequently evaporates to leave a lubricant coating
17.
Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications
The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure relates to omnipolar imaging for generating a substantially 360 degree by 180 degree stereo spherical view. The omnipolar imaging device comprises at least three wide angle lenses facing in a first direction and at least three wide angle lenses facing in a second direction opposite to the first direction, each lens connected to an image sensor. The lens are positioned so as to capture the substantially 360 degree by 180 degree view. The method of rendering the view comprises, for each pixel in an output image, selecting one set of lenses, i.e. the first set of lenses or the second set of lenses, selecting one lens from the selected set of lenses, and rendering the pixel in an output image from a corresponding point in an input image of the selected lens.
G03B 37/04 - Panoramic or wide-screen photographyPhotographing extended surfaces, e.g. for surveyingPhotographing internal surfaces, e.g. of pipe with cameras or projectors providing touching or overlapping fields of view
G03B 35/08 - Stereoscopic photography by simultaneous recording
H04N 13/271 - Image signal generators wherein the generated image signals comprise depth maps or disparity maps
A system for and a method of processing signals sensed from a user. The method comprises accessing positions of a line of sight of the user over a time frame, a first set of data associated with a first physiological signal and a second physiological signal. The method further comprises executing, by a processor, for at least one position of the positions of the line of sight of the user, identifying a first subset of data from the first set of data, identifying a second subset of data from the second set of data, associating the at least one position with the first subset of data and the second subset of data and causing to generate, by a machine-learning algorithm, a predicted value reflective of a pattern associated with the user. The method also comprises storing the predicted value associated with the at least one position.
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of CD36-related diseases, disorders or conditions in a subject, such as atherosclerosis and age-related macular degeneration.
A mixture of polymers with lubricating properties is provided. The polymer can be used to produce a lubricating fluid. They can also be born on a surface or embedded in a porous material. This mixture of polymers comprises (a) a pharmaceutically acceptable bottle-brush polymer comprising a backbone with polymeric pendant chains, and (b) a pharmaceutically acceptable linear polymer. In the lubricating fluid, the bottle-brush polymer and the linear polymer are dissolved together in a pharmaceutically acceptable solvent.
C08L 51/06 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers grafted on to homopolymers or copolymers of aliphatic hydrocarbons containing only one carbon-to-carbon double bond
A method for generating a 360 degree view. N input images are captured from N cameras fixed at a baseline height equidistantly about a circle in an omnipolar camera setup where N≧3. Two epipolar lines are defined per field of view from the cameras to divide the field of view of each one of the cameras into four parts. Image portions from each one of the cameras are stitched together along vertical stitching planes passing through the epipolar lines. Regions corresponding to a visible camera are removed from the image portions using deviations performed along the epipolar lines. Output images are formed for left and right eye omnistereo views by stitching together the first one of the four parts from each one of the fields of view and the second one of the four parts from each one of the fields of view, respectively.
G03B 37/04 - Panoramic or wide-screen photographyPhotographing extended surfaces, e.g. for surveyingPhotographing internal surfaces, e.g. of pipe with cameras or projectors providing touching or overlapping fields of view
23.
Antigenic epitopes from EBV gp350/220 and uses thereof
The present invention relates to a peptide comprising (A) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence PDDRTLQ (SEQ ID NO:1); and (ii) a second domain covalently linked to the first domain and comprising an amino acid sequence having at least 60% sequence similarity with the sequence QNPVYLIPETVPYIKWDN (SEQ ID NO:2) or (B) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence GSAKPGNGSYF (SEQ ID NO: 41); and (ii) a second domain covalently linked to the first domain, said second domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence SVKTEMLGNEID (SEQ ID NO: 42), wherein the peptide binds to monoclonal antibody clone 72A1. This peptide may be useful for inducing the production of neutralizing antibodies against a gp350-expressing herpesvirus, such as Epstein-Barr virus (EBV), for example for immunizing or vaccinating an animal against a gp350-expressing herpesvirus, as well as for detecting the presence or absence neutralizing anti-gp350-expressing herpesvirus antibodies in a sample.
The present disclosure provides target detection and quantification systems as well as related methods based on the use of steric hindrance (either created by the target itself or a macromolecular entity used to bind to the target) to prevent or limit the hybridizing between an anchoring oligonucleotide (associated to a substrate) and a signaling oligonucleotide or a combination of signaling oligonucleotides (capable of specifically binding the target or the macromolecular entity).
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A61K 39/00 - Medicinal preparations containing antigens or antibodies
26.
Method of growing a graphene coating or carbon nanotubes on a catalytic substrate
red is the partial pressure of reducing species in the atmosphere. A catalytic substrate coated with a graphene coating grown according to this method is also provided.
C23C 16/01 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes on temporary substrates, e.g. on substrates subsequently removed by etching
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
The present disclosure relates to omnipolar imaging for generating a substantially 360 degree by 180 degree stereo spherical view. The omnipolar imaging device comprises at least three wide angle lenses facing in a first direction and at least three wide angle lenses facing in a second direction opposite to the first direction, each lens connected to an image sensor. The lens are positioned so as to capture the substantially 360 degree by 180 degree view. The method of rendering the view comprises, for each pixel in an output image, selecting one set of lenses, i.e. the first set of lenses or the second set of lenses, selecting one lens from the selected set of lenses, and rendering the pixel in an output image from a corresponding point in an input image of the selected lens.
A Raman scattering probe, and a method of making such a probe, uses a capsule of nanometric size, such as a nanotube, to which is coupled at least one Raman-active molecule. The Raman-active molecule may be encapsulated in, or attached on the exterior of, the capsule, and exhibits a Raman scattering response when the probe is illuminated by an excitation light beam. A functionalization chemical group that is attached to an exterior of the capsule provides a connection between the capsule and a target material. This functionalization may include a generic chemical functionalization that bonds with any of a plurality of secondary chemical groups each of which bonds directly with a different target. A method of using the probe for Raman spectroscopy or Raman imaging is also provided.
A system for and a method of processing signals sensed from a user. The method comprises accessing positions of a line of sight of the user over a time frame, a first set of data associated with a first physiological signal and a second physiological signal. The method further comprises executing, by a processor, for at least one position of the positions of the line of sight of the user, identifying a first subset of data from the first set of data, identifying a second subset of data from the second set of data, associating the at least one position with the first subset of data and the second subset of data and causing to generate, by a machine- learning algorithm, a predicted value reflective of a pattern associated with the user. The method also comprises storing the predicted value associated with the at least one position.
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 5/16 - Devices for psychotechnicsTesting reaction times
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
30.
METHOD OF AND SYSTEM FOR PROCESSING SIGNALS SENSED FROM A USER
A system for and a method of processing signals sensed from a user. The method comprises accessing positions of a line of sight of the user over a time frame, a first set of data associated with a first physiological signal and a second physiological signal. The method further comprises executing, by a processor, for at least one position of the positions of the line of sight of the user, identifying a first subset of data from the first set of data, identifying a second subset of data from the second set of data, associating the at least one position with the first subset of data and the second subset of data and causing to generate, by a machine- learning algorithm, a predicted value reflective of a pattern associated with the user. The method also comprises storing the predicted value associated with the at least one position.
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 5/16 - Devices for psychotechnicsTesting reaction times
G06F 15/18 - in which a program is changed according to experience gained by the computer itself during a complete run; Learning machines (adaptive control systems G05B 13/00;artificial intelligence G06N)
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
31.
Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhibition of the formation and accumulation such RNA foci, as well as for the treatment of polynucleotide repeat disorders (e.g., trinucleotide repeat disorders), such as myotonic dystrophy (e.g., DM1). Such compounds include compounds of formula 1, 1a, 1b, 2, 2a and (3) described herein.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
32.
AZASULFURYLPEPTIDE-BASED CD36 MODULATORS AND USES THEREOF
Novel azasulfuryl-containing peptidomimetics capable of inhibiting CD36 activity are disclosed. Use of these azasulfuryl-containing peptidomimetics for the treatment of CD36-related diseases, disorders or conditions, including TLR2-mediated inflammatory disease, disorder or condition, and methods of obtaining such azasulfuryl-containing peptidomimetics, are also disclosed.
There are provided non-destructive methods for incorporating an atom such as N into a material such as graphene. The methods can comprise subjecting a gas comprising the atom to conditions to obtain a flowing plasma afterglow then exposing the material to the flowing plasma afterglow. There are also provided materials such as N-doped graphene produced by such methods.
C30B 31/08 - Diffusion or doping processes for single crystals or homogeneous polycrystalline material with defined structureApparatus therefor by contacting with diffusion material in the gaseous state the diffusion materials being a compound of the elements to be diffused
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
C08J 3/00 - Processes of treating or compounding macromolecular substances
C23C 8/06 - Solid state diffusion of only non-metal elements into metallic material surfacesChemical surface treatment of metallic material by reaction of the surface with a reactive gas, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using gases
H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
H01L 29/20 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds
H01J 37/317 - Electron-beam or ion-beam tubes for localised treatment of objects for changing properties of the objects or for applying thin layers thereon, e.g. ion implantation
There is provided a 3D virtual environment interaction system comprising: a processing unit for generating a 3D virtual environment comprising a planar reference frame for allowing a user to perform a user interaction with the 3D virtual environment; a display unit for displaying the generated 3D virtual environment; a portable input device for allowing the user to control the position and orientation of the planar reference frame within the generated 3D virtual environment, the portable input device comprising a planar input surface; a position and orientation sensor for monitoring the position and orientation of the planar input surface in a real-world space, the position and orientation sensor allowing the processing unit to modify at least one of the position and the orientation of the planar reference frame in response to a change in a corresponding one of the position and orientation of the planar input surface.
G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts
G06F 1/16 - Constructional details or arrangements
G06F 3/038 - Control and interface arrangements therefor, e.g. drivers or device-embedded control circuitry
G06F 3/0481 - Interaction techniques based on graphical user interfaces [GUI] based on specific properties of the displayed interaction object or a metaphor-based environment, e.g. interaction with desktop elements like windows or icons, or assisted by a cursor's changing behaviour or appearance
G06F 3/0484 - Interaction techniques based on graphical user interfaces [GUI] for the control of specific functions or operations, e.g. selecting or manipulating an object, an image or a displayed text element, setting a parameter value or selecting a range
G06F 3/0488 - Interaction techniques based on graphical user interfaces [GUI] using specific features provided by the input device, e.g. functions controlled by the rotation of a mouse with dual sensing arrangements, or of the nature of the input device, e.g. tap gestures based on pressure sensed by a digitiser using a touch-screen or digitiser, e.g. input of commands through traced gestures
G06F 3/0346 - Pointing devices displaced or positioned by the userAccessories therefor with detection of the device orientation or free movement in a 3D space, e.g. 3D mice, 6-DOF [six degrees of freedom] pointers using gyroscopes, accelerometers or tilt-sensors
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
There is provided a 3D virtual environment interaction system comprising: a processing unit for generating a 3D virtual environment comprising a planar reference frame for allowing a user to perform a user interaction with the 3D virtual environment; a display unit for displaying the generated 3D virtual environment; a portable input device for allowing the user to control the position and orientation of the planar reference frame within the generated 3D virtual environment, the portable input device comprising a planar input surface; a position and orientation sensor for monitoring the position and orientation of the planar input surface in a real-world space, the position and orientation sensor allowing the processing unit to modify at least one of the position and the orientation of the planar reference frame in response to a change in a corresponding one of the position and orientation of the planar input surface.
There is described a camera setup for capturing omnistereo images using a minimum of three cameras with ultra wide angle lenses and a method for generating a substantially 360 degree view from images taken from the cameras. The field of view covered in stereo may be a dome. The baseline between pairs of cameras defines epipoles which can be used for stitching without any horizontal misalignments due to parallax. The method comprises capturing the images from a plurality of cameras fixed at a baseline height substantially equidistantly about a circle; and stitching together portions of the images from each one of the plurality of cameras along first and second borders corresponding at least in part to lines joining center points of neighboring ones of the plurality of cameras.
G03B 35/08 - Stereoscopic photography by simultaneous recording
G03B 37/04 - Panoramic or wide-screen photographyPhotographing extended surfaces, e.g. for surveyingPhotographing internal surfaces, e.g. of pipe with cameras or projectors providing touching or overlapping fields of view
G06T 3/40 - Scaling of whole images or parts thereof, e.g. expanding or contracting
A method of preventing or treating a retinal ganglion cell (RGC) degeneration comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of a specific soluble TNFα inhibitor. Compositions and kits comprising a therapeutically or prophylactically effective amount of a specific soluble TNFα inhibitor.
The present disclosure provides target detection and quantification systems as well as related methods based on the use of steric hindrance (either created by the target itself or a macromolecular entity used to bind to the target) to prevent or limit the hybridizing between an anchoring oligonucleotide (associated to a substrate) and a signaling oligonucleotide or a combination of signaling oligonucleotides (capable of specifically binding the target or the macromolecular entity).
The present disclosure provides target detection and quantification systems as well as related methods based on the use of steric hindrance (either created by the target itself or a macromolecular entity used to bind to the target) to prevent or limit the hybridizing between an anchoring oligonucleotide (associated to a substrate) and a signaling oligonucleotide or a combination of signaling oligonucleotides (capable of specifically binding the target or the macromolecular entity).
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
The present invention relates to a peptide comprising (A) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence PDDRTLQ (SEQ ID NO:1 ); and (ii) a second domain covalently linked to the first domain and comprising an amino acid sequence having at least 60% sequence similarity with the sequence QNPVYLIPETVPYIKWDN (SEQ ID NO:2) or (B) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence GSAKPGNGSYF (SEQ ID NO: 41 ); and (ii) a second domain covalently linked to the first domain, said second domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence SVKTEMLGNEID (SEQ ID NO: 42), wherein the peptide binds to monoclonal antibody clone 72A1. This peptide may be useful for inducing the production of neutralizing antibodies against a gp350-expressing herpesvirus, such as Epstein-Barr virus (EBV), for example for immunizing or vaccinating an animal against a gp350-expressing herpesvirus, as well as for detecting the presence or absence neutralizing anti-gp350-expressing herpesvirus antibodies in a sample.
The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.
Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhibition of the formation and accumulation such RNA foci, as well as for the treatment of polynucleotide repeat disorders (e.g., trinucleotide repeat disorders), such as myotonic dystrophy (e.g., DM1). Such compounds include compounds of formula 1, 1a, 1b, 2, 2a and (3) described herein.
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 217/08 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 311/84 - Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
C07D 317/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
There is described a camera setup for capturing omnistereo images using a minimum of three cameras with ultra wide angle lenses. The field of view it covers in stereo may be a dome. The baseline between pairs of cameras defines epipoles which can be used for stitching without any horizontal misalignments due to parallax.
G03B 37/04 - Panoramic or wide-screen photographyPhotographing extended surfaces, e.g. for surveyingPhotographing internal surfaces, e.g. of pipe with cameras or projectors providing touching or overlapping fields of view
G03B 35/08 - Stereoscopic photography by simultaneous recording
A helmet for optical measurements comprises a helmet body. The helmet body is one of rigid and semi-rigid. The helmet body has an inside at least partially congruent with a shape of a head. The helmet body has at least one aperture. At least one probe is connected to the helmet body. The at least one probe is disposed within the at least one aperture. A pressure assembly is connected to the at least one probe and the helmet body. When the helmet is disposed onto a head, the pressure assembly presses the at least one probe toward the head.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
46.
METHOD AND SYSTEM FOR OPTICALLY INVESTIGATING A TISSUE OF A SUBJECT
There is described a probe device for optically investigating a tissue of a subject, comprising: a first probe element, a second probe element, and a third probe element each to be positioned at a respective vertex of a triangle for sensing the tissue, the first probe element each comprising a first light source for emitting light having a first wavelength, the second probe element each comprising a second light source for emitting light having a second wavelength and a first photodetector for detecting light having the first wavelength and scattered by the tissue, and the third probe element comprising a second photodetector for detecting light having the first and second wavelengths and scattered by the tissue.
A method for assessing a subject perception of a stimulus property, comprising: applying to a subject at least a first sensory stimulus having a first value for the stimulus property and a second sensory stimulus having a second value for the stimulus property different from the first value; requesting the subject to identify a characteristic of the first and second sensory stimuli during the application thereof, the characteristic being unrelated to the stimulus property to be assessed, thereby focusing an attention of the subject on a decision making task; measuring an activity of at least one brain region of the subject during the application of the first and second sensorial stimuli and the identification of the characteristic thereof, thereby obtaining a brain activity measurement; and determining a difference of stimulus property perceived by the subject between the first and second sensory stimuli from the brain activity measurement.
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 3/028 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing visual acuitySubjective types, i.e. testing apparatus requiring the active assistance of the patient for determination of refraction, e.g. phoropters
48.
Peptidomimetics comprising N-amino cyclic urea residues and uses thereof
Novel peptidomimetics comprising N-amino cyclic urea residues are disclosed. Use of such peptidomimetics for modulating the activity of CD36 or IL-1 receptor in a cell, and for treating CD36- or IL-1-related disease, disorder or condition is also described.
A Raman scattering probe, and a method of making such a probe, uses a capsule of nanometric size, such as a nanotube, to which is coupled at least one Raman-active molecule. The Raman-active molecule may be encapsulated in, or attached on the exterior of the capsule, and exhibits a Raman scattering response when the probe is illuminated by an excitation light beam. A functionalization chemical group that is attached to an exterior of the capsule provides a connection between the capsule and a target material. This functionalization may include a generic chemical functionalization that bonds with any of a plurality of secondary chemical groups each of which bonds directly with a different target. A method of using the probe for Raman spectroscopy or Raman imaging is also provided.
The use of a redox-active ionic liquid as an additive in an electrolyte of a secondary battery or supercapacitor, the redox-active ionic liquid comprising a redox shuttle linked to an ionic liquid is provided. Further, there is also provided such redox-active ionic liquids and electrolytes comprising such redox-active ionic liquids. There is also provided a method of manufacturing such redox-active ionic liquid electrolyte additives as well as methods of increasing the solubility of a redox shuttle in an electrolyte, manufacturing an electrolyte, manufacturing a battery or supercapacitor, increasing the stability of an electrolyte, improving the safety of a battery or supercapacitor, and reducing the risks of overcharge or overdischarge of a battery or supercapacitor.
The present disclosure relates to the preparation of azomethine and acylhydrazone polymers, and also to the dynamic polymerization of such polymers. The present disclosure further relates to conjugated fluorescent azomethine polymers and copolymers. The disclosure also includes azomethine compounds and polymers having electrochromic properties, as well as the use of such compounds in electrochromic devices.
C08G 73/00 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen, with or without oxygen or carbon, not provided for in groups
C07D 333/26 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
A Raman scattering probe, and a method of making such a probe, uses a capsule of nanometric size, such as a nanotube, to which is coupled at least one Raman-active molecule. The Raman-active molecule may be encapsulated in, or attached on the exterior of, the capsule, and exhibits a Raman scattering response when the probe is illuminated by an excitation light beam. A functionalization chemical group that is attached to an exterior of the capsule provides a connection between the capsule and a target material. This functionalization may include a generic chemical functionalization that bonds with any of a plurality of secondary chemical groups each of which bonds directly with a different target. A method of using the probe for Raman spectroscopy or Raman imaging is also provided.
B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
G01N 33/483 - Physical analysis of biological material
53.
High sensitivity plasmonic structures for use in surface plasmon resonance sensors and method of fabrication thereof
There is disclosed a method for fabricating a plasmonic structure for use in a surface plasmon resonance sensor, comprising: coating a surface of an optically clear substrate with a monolayer of microspheres forming a sphere mask; etching the sphere mask to produce an array of microholes; depositing an adsorption layer on the etched sphere mask and the surface of the optically clear substrate; depositing a metallic film on the adsorption layer; and removing the sphere mask. This is also disclosed a plasmonic structure for use in a surface plasmon resonance sensor, comprising: an adsorption layer; and a metallic film deposited on the adsorption layer; wherein the adsorption layer and the metallic film comprises an array of microholes.
Reagents, methods, constructs and kits are described for immobilizing or purifying a target RNA of interest, based on the interaction of boxB RNA with a bacteriophage N peptide, which in turn is linked to an immobilizing moiety capable of binding to a solid support.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
55.
High resolution surface plasmon resonance instrument using a dove prism
A surface plasmon resonance instrument and measuring method, in which a lens collimates light into a light beam, a prism propagates the collimated light beam at a single propagation angle and with internal reflection on a face of the prism, and an analyzer processes the collimated light beam from the prism. The face of the prism is configured to receive a surface plasmon resonance sensor and at least the first lens and the prism are aligned on a single optical axis.
Methods, uses, compositions and kits for modulating HIV replication based on PD-1 modulation are disclosed. Methods, uses, compositions and kits useful for the elimination of latent HIV reservoirs based on PD-1 inhibition are also disclosed. Methods and kits useful for identifying agents useful for modulating HIV replication are also disclosed.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
The present invention relates to the use of a porcine lung epithelial cell line that has the characteristics of the porcine lung epithelial cell line SJPL in the diagnostic and production of the porcine reproductive and respiratory syndrome (PRRS) virus.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
60.
STREPTOCOCCUS SUIS POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND THEIR USE IN VACCINAL AND DIAGNOSTIC APPLICATIONS
The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
patents
